Magle Chemoswed Holding
4.50 SEK
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.45 %
+13.64 %
-59.09 %
-74.43 %
-77.50 %
-84.48 %
-85.04 %
-88.48 %
-77.60 %
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. The Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
132.75M SEK
Turnover
-
Revenue
282.92M
EBIT %
-44.88 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18/5
2026
Interim report Q1'26
26/5
2026
General meeting '26
5/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Magle Chemoswed Holding AB (publ) announces successful completion of the written procedure in relation to its senior secured bonds 2025/2028
Magle Group Publishes Information Document in Connection with Upcoming Rights Issue
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools